Pharmathene Inc (PIP) 1.31 $PIP
PharmAthene wins US patent for rBChE bioscavenger as medical countermeasure for nerve agent poisoning in military and civilian victims
M2 - Tue Jun 10, 5:13AM CDT
Biodefence company PharmAthene (NYSE MKT
IP) revealed on Monday the receipt of the US patent number 8,729,245 that cover methods for the production of its recombinant butyrlcholinesterase (rBChE) bioscavenger in mammalian cells from the US Patent and Trademark Office.
PharmAthene Granted U.S. Patent For Recombinant Bioscavenger
PR Newswire - Mon Jun 09, 9:30AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that the U.S. Patent and Trademark Office issued U.S. patent number 8,729,245 to PharmAthene, with claims that cover methods for the production of its recombinant butyrlcholinesterase (rBChE) bioscavenger in mammalian cells. PharmAthene is initially developing rBChE as a pre- and post-exposure therapy for military and civilian victims of nerve agent attacks.
PharmAthene Presents New SparVax® Anthrax Vaccine Data At The FDA Medical Countermeasures Initiative Symposium
PR Newswire - Wed Jun 04, 9:30AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that new data from its SparVax® anthrax vaccine program were recently presented at the 2014 U.S. Food and Drug Administration (FDA) Medical Countermeasures Initiative (MCMi) Regulatory Science Symposium in Silver Spring, MD.
PharmAthene Presents New SparVax® Anthrax Vaccine Data At The American Society For Microbiology 2014 Meeting
PR Newswire - Thu May 29, 9:29AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that new analytical data from the Company's SparVax® anthrax vaccine program were presented at the 114th General Meeting of the American Society for Microbiology (ASM), held recently in Boston, Massachusetts.
Nerve Gas & Pestiside Poisioning - Pipeline Review, H1 2014 Featuring Baxter International, PharmAthene, Protalix BioTherapeutics & MicroDose Therapeutx
M2 - Wed May 28, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjpzkr/nerve_gas_and) has announced the addition of the "Nerve Gas & Pestiside Poisioning - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Nerve Gas & Pestiside Poisioning, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nerve Gas & Pestiside Poisioning and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - PharmAthene, Inc. - Protalix BioTherapeutics, Inc. - MicroDose Therapeutx, Inc. For more information visit http://www.researchandmarkets.com/research/hj...ve_gas_and
PharmAthene Presents SparVax® Anthrax Vaccine Data at the New Technologies New Vaccines 2014 Conference
PR Newswire - Tue Apr 01, 1:42PM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax® next-generation anthrax vaccine program were recently presented at the 8th Annual New Technologies, New Vaccines conference. In a presentation entitled, "Factors that Affect Potency and Stability for a Recombinant Protective Antigen Vaccine," Dr. Bradford Powell, Director, Analytical Sciences at PharmAthene, presented results demonstrating the Company's achievements in developing key analytical assays which are being employed to monitor the stability and potency of SparVax®.
PharmAthene Reports Year-End 2013 Financial And Operational Results
PR Newswire - Tue Mar 11, 3:00PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the year ended December 31, 2013.
PharmAthene to Host Year-End 2013 Conference Call and Webcast on Tuesday, March 11, 2014
PR Newswire - Mon Mar 10, 11:20AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial and operational results for the year ended 2013 will be released on Tuesday, March 11, 2014.
FTC Grants Early Termination of Hart-Scott-Rodino Act Waiting Period for Merger Transaction between Kroger and Harris Teeter
PR Newswire - Fri Jan 17, 4:34PM CST
The Kroger Co. (NYSE: KR) ("Kroger"
and Harris Teeter Supermarkets, Inc. (NYSE: HTSI) ("Harris Teeter" announced that the Federal Trade Commission today granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR" with respect to the pending merger transaction between the two companies.
Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment
PR Newswire - Tue Jan 14, 11:30AM CST
Dynamic Healthcare Services, Inc. ("DHS" , a portfolio company of GMH Ventures LLC ("GMH" , announced today that it acquired Progressive Home Medical Equipment, Inc. ("Progressive" of Clarion, PA on January 7, 2014. The terms of the acquisition were not disclosed.
Consider Buy Rated Stocks Under Five Bucks as Stocking Stuffers
at The Street - Mon Dec 23, 9:28AM CST
Advanced Micro and Alaska Communications lead nine stocks trading under $5 as speculative stocking stuffers for possible positive returns in 2014.
PharmAthene Inc's SparVax rPA anthrax vaccine programme put on clinical hold by US FDA
M2 - Tue Dec 17, 5:30AM CST
PharmAthene Inc (NYSE MKT IP) said on Monday that the U.S. Food and Drug Administration (FDA) has placed its SparVax rPA anthrax vaccine programme on clinical hold.
PharmAthene Receives FDA Notification On SparVax®
PR Newswire - Mon Dec 16, 7:00AM CST
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today it has received notification from the U.S. Food and Drug Administration (FDA) that its SparVax® rPA anthrax vaccine program has been placed on clinical hold. The Agency indicated that the Company will receive a letter providing details of the basis for the clinical hold within thirty days. The Phase II clinical study, which was expected to begin by the end of this year, has not enrolled any subjects to date and accordingly, there have been no adverse events reported.
New Non-Clinical Data Confirm SparVax® Anthrax Vaccine Can Provide Protection Against Lethal Anthrax Challenge
PR Newswire - Fri Sep 13, 7:34AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that new non-clinical animal data from the Company's SparVax® next-generation anthrax vaccine program were presented at the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Co. The data presented showed that immunization with SparVax® provides dose-dependent protection against lethal anthrax infection.
Investors look to Lighten Up on Shares of PharmAthene, Shares Down 6.2% (PIP)
Comtex SmarTrend(R) - Tue Sep 10, 10:15AM CDT
PharmAthene (AMEX IP) is one of today's worst performing low-priced stocks, down 6.2% to $1.97 on 1.0x average daily volume. Thus far today, PharmAthene has traded 369,000 shares, vs. average volume of 351,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's 0.7%) and underperformed the S&P 500 (-6.2% to the S&P's 0.7%) during today's trading.
PharmAthene Inc files registration statement in connection with its merger with Theraclone Sciences Inc
M2 - Tue Sep 10, 7:25AM CDT
PharmAthene Inc (NYSE MKT IP) said on Monday that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC) in connection with its merger with Theraclone Sciences Inc.
PharmAthene Files Registration Statement On Form S-4 With The Securities and Exchange Commission
PR Newswire - Mon Sep 09, 7:20AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC) containing a preliminary proxy statement / prospectus / consent solicitation in connection with the previously announced merger between PharmAthene, Inc., and Theraclone Sciences, Inc., a privately-held monoclonal antibody (mAb) discovery and development company.
PharmAthene Presents New SparVax® Data At The Bacillus - ACT 2013 International Anthrax Conference
PR Newswire - Fri Sep 06, 12:00PM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that new data from the Company's SparVax® next-generation anthrax vaccine program were presented in two separate oral presentations at the 2013 Bacillus - ACT international anthrax conference in Victoria, British Columbia, Canada.
PharmAthene to Present at Rodman & Renshaw Annual Global Investment Conference
PR Newswire - Tue Sep 03, 7:00AM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that Eric I. Richman, President and Chief Executive Officer will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 9, 2013 at 10:25 a.m. EDT in Room 7.03, 7th Floor of the Millennium Broadway Hotel, New York.
Hot Stock: PharmAthene, Shares Gain 8.3% (PIP)
Comtex SmarTrend(R) - Mon Aug 26, 11:43AM CDT
PharmAthene (AMEX IP) is one of today's best performing low-priced stocks, up 8.3% to $2.36 on 3.7x average daily volume. Thus far today, PharmAthene has traded 924,000 shares, vs. average volume of 250,000 shares per day. The stock has outperformed the Dow (8.3% to the Dow's 0.2%) and outperformed the S&P 500 (8.3% to the S&P's 0.3%) during today's trading.
PharmAthene wins US patent for rBChE bioscavenger as medical countermeasure for nerve agent poisoning in military and civilian victims
M2 - Tue Jun 10, 5:13AM CDT
Biodefence company PharmAthene (NYSE MKT
IP) revealed on Monday the receipt of the US patent number 8,729,245 that cover methods for the production of its recombinant butyrlcholinesterase (rBChE) bioscavenger in mammalian cells from the US Patent and Trademark Office. PharmAthene Granted U.S. Patent For Recombinant Bioscavenger
PR Newswire - Mon Jun 09, 9:30AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that the U.S. Patent and Trademark Office issued U.S. patent number 8,729,245 to PharmAthene, with claims that cover methods for the production of its recombinant butyrlcholinesterase (rBChE) bioscavenger in mammalian cells. PharmAthene is initially developing rBChE as a pre- and post-exposure therapy for military and civilian victims of nerve agent attacks.
PharmAthene Presents New SparVax® Anthrax Vaccine Data At The FDA Medical Countermeasures Initiative Symposium
PR Newswire - Wed Jun 04, 9:30AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that new data from its SparVax® anthrax vaccine program were recently presented at the 2014 U.S. Food and Drug Administration (FDA) Medical Countermeasures Initiative (MCMi) Regulatory Science Symposium in Silver Spring, MD.
PharmAthene Presents New SparVax® Anthrax Vaccine Data At The American Society For Microbiology 2014 Meeting
PR Newswire - Thu May 29, 9:29AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that new analytical data from the Company's SparVax® anthrax vaccine program were presented at the 114th General Meeting of the American Society for Microbiology (ASM), held recently in Boston, Massachusetts.
Nerve Gas & Pestiside Poisioning - Pipeline Review, H1 2014 Featuring Baxter International, PharmAthene, Protalix BioTherapeutics & MicroDose Therapeutx
M2 - Wed May 28, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjpzkr/nerve_gas_and) has announced the addition of the "Nerve Gas & Pestiside Poisioning - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Nerve Gas & Pestiside Poisioning, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nerve Gas & Pestiside Poisioning and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - PharmAthene, Inc. - Protalix BioTherapeutics, Inc. - MicroDose Therapeutx, Inc. For more information visit http://www.researchandmarkets.com/research/hj...ve_gas_and
PharmAthene Presents SparVax® Anthrax Vaccine Data at the New Technologies New Vaccines 2014 Conference
PR Newswire - Tue Apr 01, 1:42PM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax® next-generation anthrax vaccine program were recently presented at the 8th Annual New Technologies, New Vaccines conference. In a presentation entitled, "Factors that Affect Potency and Stability for a Recombinant Protective Antigen Vaccine," Dr. Bradford Powell, Director, Analytical Sciences at PharmAthene, presented results demonstrating the Company's achievements in developing key analytical assays which are being employed to monitor the stability and potency of SparVax®.
PharmAthene Reports Year-End 2013 Financial And Operational Results
PR Newswire - Tue Mar 11, 3:00PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the year ended December 31, 2013.
PharmAthene to Host Year-End 2013 Conference Call and Webcast on Tuesday, March 11, 2014
PR Newswire - Mon Mar 10, 11:20AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial and operational results for the year ended 2013 will be released on Tuesday, March 11, 2014.
FTC Grants Early Termination of Hart-Scott-Rodino Act Waiting Period for Merger Transaction between Kroger and Harris Teeter
PR Newswire - Fri Jan 17, 4:34PM CST
The Kroger Co. (NYSE: KR) ("Kroger"
and Harris Teeter Supermarkets, Inc. (NYSE: HTSI) ("Harris Teeter" announced that the Federal Trade Commission today granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR" with respect to the pending merger transaction between the two companies. Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment
PR Newswire - Tue Jan 14, 11:30AM CST
Dynamic Healthcare Services, Inc. ("DHS"
, a portfolio company of GMH Ventures LLC ("GMH" , announced today that it acquired Progressive Home Medical Equipment, Inc. ("Progressive" of Clarion, PA on January 7, 2014. The terms of the acquisition were not disclosed. Consider Buy Rated Stocks Under Five Bucks as Stocking Stuffers
at The Street - Mon Dec 23, 9:28AM CST
Advanced Micro and Alaska Communications lead nine stocks trading under $5 as speculative stocking stuffers for possible positive returns in 2014.
PharmAthene Inc's SparVax rPA anthrax vaccine programme put on clinical hold by US FDA
M2 - Tue Dec 17, 5:30AM CST
PharmAthene Inc (NYSE MKT
IP) said on Monday that the U.S. Food and Drug Administration (FDA) has placed its SparVax rPA anthrax vaccine programme on clinical hold. PharmAthene Receives FDA Notification On SparVax®
PR Newswire - Mon Dec 16, 7:00AM CST
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today it has received notification from the U.S. Food and Drug Administration (FDA) that its SparVax® rPA anthrax vaccine program has been placed on clinical hold. The Agency indicated that the Company will receive a letter providing details of the basis for the clinical hold within thirty days. The Phase II clinical study, which was expected to begin by the end of this year, has not enrolled any subjects to date and accordingly, there have been no adverse events reported.
New Non-Clinical Data Confirm SparVax® Anthrax Vaccine Can Provide Protection Against Lethal Anthrax Challenge
PR Newswire - Fri Sep 13, 7:34AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that new non-clinical animal data from the Company's SparVax® next-generation anthrax vaccine program were presented at the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Co. The data presented showed that immunization with SparVax® provides dose-dependent protection against lethal anthrax infection.
Investors look to Lighten Up on Shares of PharmAthene, Shares Down 6.2% (PIP)
Comtex SmarTrend(R) - Tue Sep 10, 10:15AM CDT
PharmAthene (AMEX
IP) is one of today's worst performing low-priced stocks, down 6.2% to $1.97 on 1.0x average daily volume. Thus far today, PharmAthene has traded 369,000 shares, vs. average volume of 351,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's 0.7%) and underperformed the S&P 500 (-6.2% to the S&P's 0.7%) during today's trading. PharmAthene Inc files registration statement in connection with its merger with Theraclone Sciences Inc
M2 - Tue Sep 10, 7:25AM CDT
PharmAthene Inc (NYSE MKT
IP) said on Monday that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC) in connection with its merger with Theraclone Sciences Inc. PharmAthene Files Registration Statement On Form S-4 With The Securities and Exchange Commission
PR Newswire - Mon Sep 09, 7:20AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC) containing a preliminary proxy statement / prospectus / consent solicitation in connection with the previously announced merger between PharmAthene, Inc., and Theraclone Sciences, Inc., a privately-held monoclonal antibody (mAb) discovery and development company.
PharmAthene Presents New SparVax® Data At The Bacillus - ACT 2013 International Anthrax Conference
PR Newswire - Fri Sep 06, 12:00PM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that new data from the Company's SparVax® next-generation anthrax vaccine program were presented in two separate oral presentations at the 2013 Bacillus - ACT international anthrax conference in Victoria, British Columbia, Canada.
PharmAthene to Present at Rodman & Renshaw Annual Global Investment Conference
PR Newswire - Tue Sep 03, 7:00AM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that Eric I. Richman, President and Chief Executive Officer will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 9, 2013 at 10:25 a.m. EDT in Room 7.03, 7th Floor of the Millennium Broadway Hotel, New York.
Hot Stock: PharmAthene, Shares Gain 8.3% (PIP)
Comtex SmarTrend(R) - Mon Aug 26, 11:43AM CDT
PharmAthene (AMEX
IP) is one of today's best performing low-priced stocks, up 8.3% to $2.36 on 3.7x average daily volume. Thus far today, PharmAthene has traded 924,000 shares, vs. average volume of 250,000 shares per day. The stock has outperformed the Dow (8.3% to the Dow's 0.2%) and outperformed the S&P 500 (8.3% to the S&P's 0.3%) during today's trading. 
